Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
30
CSLLY Quote, Financials, Valuation and Earnings
Last price:
$58.19
Seasonality move
:
4.85%
Day range:
$57.89 - $59.14
52-week range:
$54.10 - $90.04
Dividend yield:
2.51%
P/E ratio:
18.84x
P/S ratio:
3.67x
P/B ratio:
4.51x
Volume:
56.3K
Avg. volume:
158.9K
1-year change:
-34.46%
Market cap:
$56.3B
Revenue:
$15.4B
EPS (TTM):
$1.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSLLY
CSL Ltd.
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $19.01 |
|
MESO
Mesoblast Ltd.
|
$20.3M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSLLY
CSL Ltd.
|
$58.17 | -- | $56.3B | 18.84x | $0.81 | 2.51% | 3.67x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.10 | $12.00 | $56.2M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$3.08 | $9.50 | $448.3M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
$8.00 | $19.01 | $13.4M | -- | $0.00 | 0% | 361.47x |
|
MESO
Mesoblast Ltd.
|
$19.40 | $35.00 | $2.5B | -- | $0.00 | 0% | 136.15x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSLLY
CSL Ltd.
|
39.2% | -0.028 | -- | 0.84x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -1.575 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.640 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 5.445 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 0.345 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSLLY
CSL Ltd.
|
$4.3B | $2B | 8.85% | 14.06% | 33.52% | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
CSL Ltd. vs. Competitors
-
Which has Higher Returns CSLLY or ATHE?
Alterity Therapeutics Ltd. has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About CSLLY or ATHE?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 288.35%. Given that Alterity Therapeutics Ltd. has higher upside potential than CSL Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is CSLLY or ATHE More Risky?
CSL Ltd. has a beta of 0.768, which suggesting that the stock is 23.235% less volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.023, suggesting its less volatile than the S&P 500 by 97.656%.
-
Which is a Better Dividend Stock CSLLY or ATHE?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.51%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or ATHE?
CSL Ltd. quarterly revenues are $8.2B, which are larger than Alterity Therapeutics Ltd. quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than Alterity Therapeutics Ltd.'s net income of --. Notably, CSL Ltd.'s price-to-earnings ratio is 18.84x while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.67x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.67x 18.84x $8.2B $2B ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns CSLLY or IMMP?
Immutep Ltd. has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About CSLLY or IMMP?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 208.44%. Given that Immutep Ltd. has higher upside potential than CSL Ltd., analysts believe Immutep Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is CSLLY or IMMP More Risky?
CSL Ltd. has a beta of 0.768, which suggesting that the stock is 23.235% less volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.925, suggesting its more volatile than the S&P 500 by 92.469%.
-
Which is a Better Dividend Stock CSLLY or IMMP?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.51%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or IMMP?
CSL Ltd. quarterly revenues are $8.2B, which are larger than Immutep Ltd. quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than Immutep Ltd.'s net income of --. Notably, CSL Ltd.'s price-to-earnings ratio is 18.84x while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.67x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.67x 18.84x $8.2B $2B IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns CSLLY or KZIA?
Kazia Therapeutics Ltd. has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About CSLLY or KZIA?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $19.01 which suggests that it could grow by 138.05%. Given that Kazia Therapeutics Ltd. has higher upside potential than CSL Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is CSLLY or KZIA More Risky?
CSL Ltd. has a beta of 0.768, which suggesting that the stock is 23.235% less volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.185%.
-
Which is a Better Dividend Stock CSLLY or KZIA?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.51%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or KZIA?
CSL Ltd. quarterly revenues are $8.2B, which are larger than Kazia Therapeutics Ltd. quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than Kazia Therapeutics Ltd.'s net income of --. Notably, CSL Ltd.'s price-to-earnings ratio is 18.84x while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.67x versus 361.47x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.67x 18.84x $8.2B $2B KZIAKazia Therapeutics Ltd.361.47x -- -- --
-
Which has Higher Returns CSLLY or MESO?
Mesoblast Ltd. has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About CSLLY or MESO?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 80.41%. Given that Mesoblast Ltd. has higher upside potential than CSL Ltd., analysts believe Mesoblast Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 MESOMesoblast Ltd.1 0 0 -
Is CSLLY or MESO More Risky?
CSL Ltd. has a beta of 0.768, which suggesting that the stock is 23.235% less volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.508%.
-
Which is a Better Dividend Stock CSLLY or MESO?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.51%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or MESO?
CSL Ltd. quarterly revenues are $8.2B, which are larger than Mesoblast Ltd. quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than Mesoblast Ltd.'s net income of --. Notably, CSL Ltd.'s price-to-earnings ratio is 18.84x while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.67x versus 136.15x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.67x 18.84x $8.2B $2B MESOMesoblast Ltd.136.15x -- -- --
-
Which has Higher Returns CSLLY or PPCB?
has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B PPCB-- -$0.00 -- -
What do Analysts Say About CSLLY or PPCB?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that CSL Ltd. has higher upside potential than , analysts believe CSL Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 PPCB0 0 0 -
Is CSLLY or PPCB More Risky?
CSL Ltd. has a beta of 0.768, which suggesting that the stock is 23.235% less volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock CSLLY or PPCB?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.51%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or PPCB?
CSL Ltd. quarterly revenues are $8.2B, which are larger than quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than 's net income of -$354.3K. Notably, CSL Ltd.'s price-to-earnings ratio is 18.84x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.67x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.67x 18.84x $8.2B $2B PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
